Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alba A Brandes

Showing results (91-100 of 178) with videos related to

Pageof 18
Sort By:
The Lancet. Oncology|December 18, 2007
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3Thierry Gorlia, Martin J van den Bent, Monika E Hegi, et al.
Neuro-Oncology|March 9, 2016
AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastomaAlba A Brandes, Gaetano Finocchiaro, Vittorina Zagonel, et al.
Neuro-Oncology|October 24, 2012
EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastomaEnrico Franceschi, Roger Stupp, Martin J van den Bent, et al.
The New England Journal of Medicine|February 21, 2014
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastomaOlivier L Chinot, Wolfgang Wick, Warren Mason, et al.
Plos One|May 19, 2017
The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinomaDario de Biase, Giovenzio Genestreti, Michela Visani, et al.
Lung Cancer (Amsterdam, Netherlands)|October 28, 2008
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from ItalyMarcello Tiseo, Cesare Gridelli, Stefano Cascinu, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2012
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trialsThierry Gorlia, Roger Stupp, Alba A Brandes, et al.
Neuro-Oncology Practice|July 20, 2022
Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101Ivan Caramanna, Julie M de Kort, Alba A Brandes, et al.
Frontiers in Oncology|July 18, 2020
Rare Primary Central Nervous System Tumors in Adults: An OverviewEnrico Franceschi, Didier Frappaz, Roberta Rudà, et al.
Oncotarget|April 28, 2016
Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancerAlessandro Passardi, Emanuela Scarpi, Luigi Cavanna, et al.
Pageof 18

Showing results (91-100 of 178) with videos related to

Sort By:
Pageof 18
The Lancet. Oncology|December 18, 2007
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3Thierry Gorlia, Martin J van den Bent, Monika E Hegi, et al.
Neuro-Oncology|March 9, 2016
AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastomaAlba A Brandes, Gaetano Finocchiaro, Vittorina Zagonel, et al.
Neuro-Oncology|October 24, 2012
EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastomaEnrico Franceschi, Roger Stupp, Martin J van den Bent, et al.
The New England Journal of Medicine|February 21, 2014
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastomaOlivier L Chinot, Wolfgang Wick, Warren Mason, et al.
Plos One|May 19, 2017
The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinomaDario de Biase, Giovenzio Genestreti, Michela Visani, et al.
Lung Cancer (Amsterdam, Netherlands)|October 28, 2008
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from ItalyMarcello Tiseo, Cesare Gridelli, Stefano Cascinu, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2012
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trialsThierry Gorlia, Roger Stupp, Alba A Brandes, et al.
Neuro-Oncology Practice|July 20, 2022
Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101Ivan Caramanna, Julie M de Kort, Alba A Brandes, et al.
Frontiers in Oncology|July 18, 2020
Rare Primary Central Nervous System Tumors in Adults: An OverviewEnrico Franceschi, Didier Frappaz, Roberta Rudà, et al.
Oncotarget|April 28, 2016
Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancerAlessandro Passardi, Emanuela Scarpi, Luigi Cavanna, et al.
Pageof 18